Skip to main content

BOOST Pharma

  • | Biotech or pharma, therapeutic R&D
BOOST Pharma

BOOST Pharma is developing a first-in-class therapy to treat Osteogenesis Imperfecta, a rare genetic disease. The Company has established a strong clinical safety data base. Recent Phase I/II showed excellent safety and high efficacy (reduction of bone fractures) in children born with OI.


Positive top-line clinical results were announced in September 2024.


FDA fully accepted in October 2024 our proposal for pivotal Ph III trial.

Address

Copenhagen
Denmark
Visit website

Contact Exhibitor


Loading
View all Exhibitors
Testimonials

Double Helix


 

Supporting Bank Sponsor


 

Premier Sponsors

Conference Sponsors